10 / 41
Notes:
Volume 6, Issue 4 (Suppl)
Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 63
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6
th
International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4
th
EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Diabetic conditions and drug vehicles alter drug metabolism
Kvell K, Varga E, Almási A, Pandur E, Horváth Gy, Bencsik T, Póor M, Pohóczky K, Pál Sz, Horváth B, Garai K
and
Perjési P
University of Pecs, Hungary
T
ype II diabetes mellitus is a chronic disease, characterized by hyperglycemia and impaired metabolism. In diabetes, several
metabolic pathways are altered, thus the biotransformation and pharmacokinetic of drugs can be influenced due to changes
in enzymes and drug transporters. Streptozotocin (STZ) is a widely used glucosamine-nitrosourea compound to induce type
II diabetes in murine models. Studies show that in STZ induced chronic uncontrolled diabetes different biotransformation
enzymes are altered. Carotenoids are a class of natural antioxidants and according to epidemiological evidences, might have a
protective role in chronic diseases. They are able to protect the body from long term consequences of diabetes, like neuronal
and eye abnormalities or infectious diseases. Carotenoids have low solubility in water, therefore cyclic oligosaccharides,
cyclodextrins can be used to improve the aqueous solubility of carotenoids. In pharmaceutical applications, cyclodextrins are
able to enhance drug permeability through gastrointestinal tissues, accordingly these cyclic compounds can be also used for
increase the bioavailability of carotenoids.
Biography
Kvell K, MD PhD has primary expertise in Immunology and Biotechnology. Currently he is working at the Department of Pharmaceutical Biotechnology, Faculty of
Pharmacy, at the University of Pecs, Hungary. He is currently involved in interdisciplinary research utilizing nanoparticles. This field encouraged the collaborative
research team to develop novel drug delivery strategies.
Kvell K et al., Clin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-026